Structural Bioinformatics
This article was originally published in Start Up
Executive Summary
Drug Discovery Tools; Bioinformatics. Structural Bioinformatics performs computational high-throughput screening with a 4-D approach to the generation of protein structures, that is, dynamic 3-D protein structures viewed through the fourth dimensionof time. It seeks to bridge the gap between novel gene-sequence data generated by genomic researchers and the 3-D structural information used by researchers in drug discovery.
You may also be interested in...
Focus on Bioinformatics
Because of the difficulty in combining knowledge of both biology and informatics in one company, the new bioinformatics start-ups reckon they can build a new service business for biotechs and for Big Pharma.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Building Long-Term Value Into Near-Term Commercial Strategy
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.